Dear compounders,
In the first part of this series (find it here), I walked through Grab, the first of seven ideas I am lining up as potential homes for the capital that would be freed up if the Ember proposal for Ashtead Technology materializes or if the gap to the offer closes.
Idea number two is a very different animal. It is a former market darling that has lost almost three-quarters of its value in just over two years, and a stock I have passed on for as long as I have been writing about it.
All my prior Novo Nordisk write-ups:
Idea #2: Novo Nordisk
What is the price trying to tell us?
Novo has been in a downtrend since June 2024. The stock is down 72.6% over roughly 2.2 years, which works out to a CAGR of about minus 44%. That is pretty bad, and yet the most important line on this chart is the black one. For almost two decades, Novo respected a long-term uptrend that started in the mid-2000s, and in 2025 it broke that line decisively.
In Part 3 of my framework series, I wrote that the longer and steeper the uptrend, the more violent the reversion when it finally breaks. Novo is a textbook case, right next to Constellation Software and Diageo (and many other recent ones come to mind such as Rollins or Intuitive Surgical). Of the two downtrend lines, the light red one probably carries the stronger signal. It covers a shorter period than the dark red one, but it has five touchpoints compared with just two, and neither line has been broken.
Clear support is hard to find. The only meaningful reference point on the downside is the March 2026 low at $34.85, roughly 10% below the current share price, and it may well get tested soon.
As I explained in Part 3 of my framework series:
Large volume spikes often signal forced behavior – capitulation, de-risking, mandate-driven selling. These are moments when decision-making is less reflective and more reactive.
High volume near peaks = bearish
High volume near troughs = bullish
Applied to Novo, the picture is sobering. The stock has traded in heavy volume throughout 2025 and 2026, with daily turnover regularly at several times its long-term average of about 7.5 million shares and multiple clear spikes along the way. More than once, a spike looked like the capitulation that marks a bottom, and more than once Novo went on to make new lows. Investing is tough and technical analysis is just one tool in your toolkit that you need to couple with many other ones and even then you might not perfectly time the lows – but does this mean you shouldn’t try?
Volume has eased somewhat from its early-2026 peaks, but it remains far above pre-selloff levels, and the latest spike in September came on the way down. That tells me the transition in ownership I described in Part 3 of my perception change analysis series (I cannot even pinpoint from whom to whom … long-term owners to those concluding that the embedded expectations at this price make up for the many mistakes of the past?) is not finished yet.
Novo has also been incredibly volatile. Since August 2025, the stock has gone through two full bull and bear cycles, rallying 42% and 46% within a few months each time and then giving back 44% and 25% even faster. Bulls take the stairs, bears ride the elevator, and Novo illustrates the saying almost perfectly.
Interestingly, the stock trades only about 11% below its August 2025 low of $43.54, and for more than a year it has been stuck in a range between roughly $35 and $62.
In the language of my framework, that looks like the early shape of a sideways base, although an unusually wild one.
The rest of this post is FREE to read. I only ask that you subscribe, which costs nothing and can be undone with a single click whenever you like.
The wall also helps keep my writing from being freely scraped by AI crawlers, so I hope you understand the small extra step.
In return, you get every deep dive, earnings review, and process piece I publish, straight to your inbox.




